Trial · NCT03126630
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group I (Pembrolizumab) | NE | 2 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group II (Anetumab Ravtansine, Pembrolizumab) | NE | 4 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group I (Pembrolizumab) | PD (Preliminary) | 6 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group II (Anetumab Ravtansine, Pembrolizumab) | PD (Preliminary) | 2 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group I (Pembrolizumab) | PD (Confirmed) | 3 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group II (Anetumab Ravtansine, Pembrolizumab) | PD (Confirmed) | 1 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group I (Pembrolizumab) | SD | 5 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group II (Anetumab Ravtansine, Pembrolizumab) | SD | 9 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group I (Pembrolizumab) | PR (Confirmed) | 1 | Participants | |
| Phase 2 Confirmed Tumor Response Rate (Phase II) | Group II (Anetumab Ravtansine, Pembrolizumab) | PR (Confirmed) | 2 | Participants | |
| Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumab | Phase 1 Cohort: Anetumab Ravtansine & MK-3475 | 6.5 | mg/kg IV | ||
| Phase 2 Overall Survival | Group I (Pembrolizumab) | 0 | Participants | ||
| Phase 2 Overall Survival | Group II (Anetumab Ravtansine, Pembrolizumab) | 2 | Participants | ||
| Phase 2 Progression Free Survival | Group I (Pembrolizumab) | 10 | Participants | ||
| Phase 2 Progression Free Survival | Group II (Anetumab Ravtansine, Pembrolizumab) | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03126630/results